ONWARD Medical Reports Robust Growth in First Half of 2026

ONWARD Medical N.V. shared its financial and operational results for the first half of 2026, highlighting significant product revenue growth and progress in its ARC Therapy pipeline. Sales of the ARC-EX® System rose by 430% compared to the previous year, now available in over 130 US clinics and expanding in the US Veterans Affairs Healthcare System. The company also made strides in its investigational ARC-IM® and ARC-BCI® systems, enrolling participants in global studies.

Financially, ONWARD reported a revenue of EUR 4.2 million and raised EUR 40.6 million in equity capital, ending the period with a cash balance of EUR 81.5 million. Despite an operating loss of EUR 23.3 million, the company's strategic investments continue to fuel growth and innovation.

CEO Dave Marver emphasized the success of the ARC-EX launch and the company's strong position to expand its offerings and pursue regulatory approvals.